MNPR — Monopar Therapeutics Share News
0.000.00%
Last trade - 00:00- $487.17m
- $352.87m
U.S. STOCKS ON THE MOVE-Medtronic, Equitrans Midstream, Super Micro
Brief: Monopar Therapeutics QTRLY Net Loss $0.14 Per Share
Brief: Monopar Presents Data Showing Tumor Reduction Benefit Of Camsirubicin From Ongoing Phase 1b At The 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Brief: Monopar Therapeutics Says On August 28 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Monopar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Monopar Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Monopar Announces MNPR-101 Radiopharma Collaboration Agreement With National University Of Singapore
U.S. STOCKS ON THE MOVE-Lands' End, Energy sector
U.S. STOCKS ON THE MOVE-Biogen, NetApp, LyondellBasell
U.S. STOCKS ON THE MOVE-Monopar Therapeutics, Molecular Templates, NRG Energy
Monopar Therapeutics jumps on early-stage trial update for cancer treatment
Brief: Monopar Announces Early-Stage Trial Update For Cancer Treatment
Brief: Monopar Therapeutics Reports Q1 2023 Financial Results And Recent Developments
Monopar Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Monopar Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Monopar Therapeutics slumps as oral mucositis drug fails in trial
Brief: Monopar Therapeutics Reports Fourth Quarter And Full-Year 2022 Financial Results
Monopar Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen To Date Compared To Doxorubicin